☏ +1 650 501 5505 ✉ [email protected]
Drug Pipeline Review Therapy area: Vitiligo40–50 pages · PDF + Excel tracker

Vitiligo Drug Pipeline: 27 Assets by Phase

Vitiligo pipeline: 27 drug candidates in clinical development, 5 in Phase III, from 25 sponsors. Data as of 6 Nov 2026.

Pipeline Terminal Vitiligo Data as of 6 Nov 2026
Candidates in development 27assets Desk-reviewed How this number is madeEvery drug named in an interventional trial, merged across code, generic and brand names, with a live or recent industry trial. Placebo and comparator arms excluded.
Phase III 519% of pipeline Registry How this number is madeCandidates whose highest phase in a live or recent trial is Phase III (Phase II/III counts as Phase II).
Phase II 1763% of pipeline Registry
Phase I 519% of pipeline Registry
Sponsors 25top 5 hold 26% Registry How this number is madeCompanies credited with at least one candidate: the lead sponsor on most of that candidate's industry trials.
Registered trials 12569 running Registry How this number is madeInterventional trials on ClinicalTrials.gov for the conditions in scope, updated since 6 Nov 2021.
Readouts in 12 months 10Phase II or later Sponsor dates How this number is madeCandidates with a registered primary completion date in the next 12 months. Dates are the sponsor's own and often move.
Trials with US sites 3931% · Europe 29% Registry How this number is madeTrials with at least one site in the United States; Europe is the EU/EEA, the UK and Switzerland. A trial counts in every region where it has a site.

Candidates by highest phase reached

Phase I5
Phase II17
Phase III5

Next registered primary completions, Phase II or later

CandidatePhasePrimary completion
QY201 ( )Phase IIDec 2026 (est.)
EI-001Phase IIDec 2026 (est.)
Melanotan IIPhase IIFeb 2027 (est.)

Candidates in development by lead sponsor

Innovent Biologics (Suzhou) Co. Ltd.2
Jiangsu HengRui Medicine Co., Ltd.2
Idorsia Pharmaceuticals Ltd.1
Clinuvel, Inc.1
CAGE Bio Inc.1

Phase II and III primary completions per quarter

Q4 20262
Q1 20275
Q2 20272
Q3 20271
Q4 20273
Q1 20283
Q2 20282
Q3 20280

Answers at a glance

  • 5 of 27 vitiligo candidates (19%) are in Phase III.
  • Innovent Biologics (Suzhou) Co. Ltd. runs the largest vitiligo pipeline, with 2 candidates.
  • 10 readouts are due in 12 months; the next is QY201 ( ) in Dec 2026.
  • 29 trials are recruiting patients now; 31% of all trials have a US site and 29% a European one.
27 candidates125 trials39 countriesData as of 6 Nov 2026Next refresh by 4 Feb 2027
USD 3,000Pipeline Snapshot Download Free Sample Request the Review
Edition: data as of 6 Nov 2026 Next refresh: by 4 Feb 2027 Change: First edition

Request a free sample

A sample of the Vitiligo Pipeline Review: the full chapter list, the tracker columns and two asset profiles from the report. The Research Desk reviews your request and emails it, usually within one business day.

Vitiligo has 27 drug candidates in active clinical development, of which 5 are in Phase III, 17 in Phase II and 5 in Phase I, according to Douglas Insights' count of 125 interventional trials registered on ClinicalTrials.gov (data as of 6 Nov 2026).

The vitiligo drug pipeline is the set of medicines that sponsors are still testing in people for this condition: each candidate is counted once, at the highest phase it has reached in a running or recently completed trial. Medicines already on the market and studied only in Phase IV trials are kept out of the count.

How many vitiligo drugs are in each phase of development?

Douglas Insights counts 5 vitiligo candidates in Phase III, 19% of the 27 assets in development; Phase II holds 17 and Phase I holds 5.

Phase I5Phase II17Phase III5
Candidates by highest phase reached. Source: Douglas Insights from ClinicalTrials.gov, data as of 6 Nov 2026.
Phase (highest reached)AssetsShare of pipeline
Phase III519%
Phase II1763%
Phase I519%
Total27100%

Phase I/II candidates sit in the Phase I row and Phase II/III candidates in the Phase II row, so each vitiligo asset appears in exactly one row. The 69 trials still recruiting or running carry 55% of the 125 registered trials in scope.

Which approved vitiligo medicines are still in trials?

1 medicines already on the market are still being tested in vitiligo Phase IV trials; Ruxolitinib cream has the most, with 13 registered trials.

MedicineLead sponsorRegistered trials
Ruxolitinib creamIncyte Corporation13

Post-approval vitiligo trials test new doses, new patient groups and head-to-head comparisons. They set the standard of care that every candidate in development will be measured against, so the paid review profiles each one.

How many vitiligo trials are recruiting patients now?

29 vitiligo trials are recruiting patients and 20 more have not started recruiting yet, out of 125 interventional trials in scope; together they make up 39% of the trial base.

Registry statusTrialsShare
Completed4133%
Recruiting2923%
Not yet recruiting2016%
Active, not recruiting1714%
Status not verified97.2%
Terminated54.0%
Enrolling by invitation32.4%
Withdrawn10.8%

Terminated, suspended and withdrawn vitiligo trials stay in the trial base so that a stalled programme is visible, but a candidate whose only trials stopped is no longer counted as in development.

Which companies lead the vitiligo pipeline?

Innovent Biologics (Suzhou) Co. Ltd. leads the vitiligo pipeline with 2 candidates; the top 5 sponsors hold 26% of the 27 assets, and 25 sponsors run at least one.

SponsorAssets in developmentShare
Innovent Biologics (Suzhou) Co. Ltd.27.4%
Jiangsu HengRui Medicine Co., Ltd.27.4%
Idorsia Pharmaceuticals Ltd.13.7%
Clinuvel, Inc.13.7%
CAGE Bio Inc.13.7%

Industry sponsors lead 55 of the 125 vitiligo trials (44%); universities, hospitals and public funders lead the rest. A sponsor is credited with an asset when it is the lead sponsor on most of that asset's industry trials.

Which drug types and mechanisms dominate the vitiligo pipeline?

Mechanism and drug-type classification for the 27 vitiligo candidates is done by the research desk asset by asset, each with a cited source, and is published in the paid review together with the white-space map.

What vitiligo trial readouts are coming next?

10 vitiligo candidates in Phase II or later have a registered primary completion date in the next 12 months; the next three are below, each linked to its registry record.

CandidateSponsorPhasePrimary completionRegistry
QY201 ( )E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.Phase IIDec 2026 (estimated)NCT07712523
EI-001Elixiron Immunotherapeutics (Hong Kong) Ltd.Phase IIDec 2026 (estimated)NCT07223229
Melanotan IIHudson BiotechPhase IIFeb 2027 (estimated)NCT07437560

Primary completion is the date a sponsor expects the last patient to finish the main measurement, so data usually follow within months. Dates marked estimated are the sponsor's own forecast on the registry and often move.

How many vitiligo readouts fall in each quarter?

18 vitiligo candidates in Phase II or later reach registered primary completion over the next eight quarters, with the most, 5, due in Q1 2027.

QuarterPhase III readoutsPhase II readoutsTotal
Q4 2026022
Q1 2027145
Q2 2027022
Q3 2027011
Q4 2027033
Q1 2028213
Q2 2028112
Q3 2028000

Each candidate is counted once, at its next readout. The paid catalyst calendar names every readout with its trial, sponsor and design, adds filings and regulatory decisions, and runs 24 months ahead.

Which countries host the most vitiligo trials?

United States hosts the most vitiligo trials, with sites in 39 of the 125 studies (31%); trials in scope run in 39 countries in all.

CountryTrials with a siteShare of trials
United States3931%
China2923%
France2520%
Canada2218%
Egypt1915%
Poland1411%
Germany1310%
Spain1310%

A multinational vitiligo trial is counted once in every country where it has a site, so the shares add up to more than 100%. Country spread shows where sponsors are building the evidence that regulators in each market will ask for.

Where are vitiligo drugs being tested?

39 of the 125 vitiligo trials (31%) have a site in the United States, 36 (29%) in Europe and 29 (23%) in China; 11 of the 27 candidates in development are tested in the US.

RegionTrials with a siteShare of trialsCandidates testedRegulator
United States3931%11FDA
Europe (EU/EEA, UK, Switzerland)3629%8EMA, MHRA, Swissmedic
China2923%17NMPA
Japan108.0%5PMDA
Rest of world6552%13national regulators

Each region's trials are the evidence its regulator will review: the FDA in the United States, the EMA (with the MHRA and Swissmedic) in Europe, the NMPA in China and the PMDA in Japan. A multinational vitiligo trial counts once in every region where it has a site, so the shares add up to more than 100%. A candidate tested only outside the US and Europe is often a licensing opportunity for sponsors in those markets.

What has changed in the vitiligo pipeline since the last update?

This is the first edition of the vitiligo pipeline count, dated 6 Nov 2026. The next refresh is due by 4 Feb 2027, and each refresh lists the assets that entered, advanced or dropped out.

How does Douglas Insights count the vitiligo pipeline?

Douglas Insights read 125 interventional trials registered on ClinicalTrials.gov for the conditions "Vitiligo" and updated since 6 Nov 2021, then grouped every drug or biologic named in them into 27 unique candidates.

  1. Code names, generic names and brand names of the same molecule are merged into one candidate, and every merge is reviewed by the research desk.
  2. A candidate counts when it has a trial that is recruiting, running, or completed in the last 24 months, and at least one industry-sponsored trial.
  3. Its phase is the highest phase among those trials; placebo, standard-of-care and comparator arms are not candidates.
  4. Each figure on this page is drawn from one frozen dataset that passes ten checks before release, and the owner approves every edition.

Read the full approach on the research methodology page, or browse other Pharmaceuticals research.

What does the Vitiligo Pipeline Review include?

The Vitiligo Pipeline Review covers all 27 candidates in an Excel tracker and profiles the leading 25 in a 40–50 page report, ending with the research desk's ranked view of the candidates most likely to win.

11 chapters40–50 pages25 asset profilesExcel tracker of all 27 candidates
01Executive summary and our call2–3 pp

The pipeline on one page and the desk's verdict on where vitiligo treatment is heading.

  • Pipeline size and phase mix
  • The three calls that matter
  • What changed since the last edition
02Disease and unmet need3 pp

Who is treated today, what current therapy leaves unmet, and how regulators judge new medicines.

  • Patient population and diagnosis
  • Treatment guidelines and gaps
  • Regulatory endpoints
03Approved therapies3 pp

The marketed medicines every vitiligo candidate will be measured against.

  • Marketed medicines and their sponsors
  • Post-approval trials
  • The bar a new entrant must clear
04Pipeline at a glance4 pp

Every candidate counted by phase, drug type, sponsor and country.

  • Assets by phase and drug type
  • Sponsors by size of pipeline
  • Trial footprint: US, Europe, China, Japan
05Mechanism landscape and white space5 pp

Which mechanisms are crowded and which no sponsor has entered.

  • Mechanism classes and crowding
  • Classes with no candidate yet
  • Differentiation by route and dosing
06Key asset profiles12–15 pp

The leading 25 candidates, one profile each, every claim linked to a source document.

  • Design and endpoints of the pivotal trials
  • Data to date, with sources
  • Next readout and the risk to it
07Catalyst calendar3 pp

Readouts, filings and regulatory decisions 24 months ahead.

  • Readouts by quarter
  • Filings and regulatory decisions
  • Date confidence for each event
08Deals and partnering3 pp

Who is licensing, buying and partnering in vitiligo, and on what terms.

  • Licensing and M&A in the area
  • Deal terms where disclosed
  • Sponsors open to partnering
09Sponsor landscape3 pp

Large pharma against biotech, and how concentrated the pipeline is.

  • Pipeline share by sponsor
  • Sponsor-by-phase matrix
  • New entrants since the last edition
10Our call: winners, risks, opportunities3–4 pp

The candidates most likely to win, ranked, with the reasoning and evidence.

  • Ranked candidates
  • Risks that could change the order
  • Openings for new entrants and investors
11Methodology and source log2 pp

How the count is built and every document behind it.

  • How candidates are counted and merged
  • Every source document listed
  • The ten quality checks

Ways to buy the Vitiligo review

OptionWhat you getDeliveryPrice
Pipeline SnapshotThis therapy area as published: PDF report + Excel trackerReady nowUSD 3,000Enquire
Pipeline ReviewYour indication, geography and phase cut-off; ranked calls and an analyst call2–3 weeksFrom USD 4,000Enquire
Company AssessmentOne sponsor's full pipeline against its peers2 weeksFrom USD 5,000Enquire

Email me the sample and chapter listAsk for a quote

Frequently asked questions about the vitiligo pipeline

How many drugs are in the vitiligo pipeline?

27 drug candidates are in active clinical development for vitiligo, with 5 in Phase III, per Douglas Insights (data as of 6 Nov 2026).

Which company has the most vitiligo drugs in development?

2 candidates make Innovent Biologics (Suzhou) Co. Ltd. the largest vitiligo pipeline sponsor, out of 25 sponsors counted by Douglas Insights.

When is the next vitiligo trial readout?

Dec 2026 is the registered primary completion of the Phase II trial of QY201 ( ) (NCT07712523), the next vitiligo catalyst in Douglas Insights' calendar.

How many vitiligo trials run in the United States and Europe?

39 vitiligo trials have a US site and 36 a European site, out of 125 registered trials counted by Douglas Insights (data as of 6 Nov 2026).

How often is the vitiligo pipeline count updated?

90 days is the refresh cycle; this edition uses registry data as of 6 Nov 2026 and the next is due by 4 Feb 2027.

Research & citation

This review was researched, written and reviewed by the Douglas Insights Research Desk under the Douglas Insights editorial standards. Material errors are logged in the corrections log. No section is sponsored.

Cite this page Douglas Insights (2026). Vitiligo Drug Pipeline, data as of 6 Nov 2026. https://www.douglasinsights.com/pipeline/vitiligo/